Navigation Links
Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
Date:4/25/2013

ATLANTA, April 25, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it will update the scientific and medical community on the development program for IkT-001Pro.  IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).  The Company will demonstrate the effectiveness of IkT-001Pro against patient-derived JCV isolated from the urine of patients chronically infected with virus, the first time a direct measure of antiviral potency against patient-derived virus has been possible.  A preliminary insight into clinical efficacy of the proposed therapy will also be presented, linking mechanism of action to direct control of virus in patients.  

(Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO)

JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression, to include patients diagnosed with clinical AIDS or who are receiving monoclonal antibody treatment for MS, lupus, rheumatoid arthritis, leukemia or lymphoma.   IkT-001Pro is projected to clear the patient of chronic JCV infection prior to its transformation and entry into the brain, thereby acting as a form of preventative therapy for AIDS patients and/or patients on immunosuppressive therapy.

"The ability to isolate and replicate patient-derived virus and demonstrate antiviral potency for IkT-001Pro validates the mechanism of action of this medication against the viral infection that actually afflicts patients.  Combined with a preliminary clinical readout, Inhibikase may have found a path to control the PML development in at least some patients.  While further clinical evaluati
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
2. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
3. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
4. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
5. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
8. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
9. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
(Date:7/30/2015)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year. Reported sales decreased 4% as currency reduced sales ... earnings per diluted share as reported (EPS) were $2.73, ... was $2.80 , an increase of 9% over ...
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... 4, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... in Phoenix, Arizona on Thursday, November 11, 2010 at 5:30 ... Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ... webcast live through the "Investors" section of Amylin,s corporate website ...
... N.C., Nov. 4, 2010 Gentris Corporation ( ... pharmacogenomics, announced today that Howard McLeod, Pharm.D., from ... (UNC) has become the Company,s first Chief Scientific ... pharmacogenomics and personalized medicine, is the Fred N. ...
Cached Medicine Technology:Gentris Corporation Names New Chief Scientific Advisor 2Gentris Corporation Names New Chief Scientific Advisor 3
(Date:7/31/2015)... , ... July 31, 2015 , ... “ Crack’em ” ... latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert and ... helps chefs make less mess while cooking. , Cooking can be a very messy ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Super-Sod wants ... with a Super-Sod Pro Page as the perfect fit for such a ... pictures and articles. The social website is a dynamic site that spreads home and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... In the most ... U.S. District Court in the Northern District of Illinois, Androgel testosterone attorneys report that ... 20, a docket entry was made recording the minutes of the status conference, which ...
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional Products ... of nutritional and wellness products, announced the addition of Vincent Aquilino to its ... active isolated stretching and the prevention and rehabilitation of injuries, has spent the ...
(Date:7/31/2015)... ... , ... Easter Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will be held Saturday, ... AM. The duathlon is a 2 mile run, 13 mile bike ride, and a 3 ... mile bike, and a 3 mile run. Heels & Wheels is sponsored by Mayo ...
Breaking Medicine News(10 mins):Health News:Make Less Mess while Cooking with Crack’em 2Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2
... , MONDAY, Dec. 5 (HealthDay News) -- When people with ... a third worrisome condition -- dementia -- goes up ... 2 diabetes are twice as likely to develop dementia three ... nondepressed people with diabetes, researchers found. "We,ve known for ...
... Calif. -- Aspirin taken within five days of cardiac ... risk of major postoperative complications, including renal failure, a ... (30-day mortality), according to a study by researchers at ... to appear in the journal Annals of Surgery ...
... been launched to help raise awareness of work being done ... childhood obesity and to seek the views of parents and ... of childhood overweight and obesity, led by a team of ... One-quarter of babies gain weight more rapidly than they should ...
... HealthDay Reporter , MONDAY, Dec. 5 (HealthDay News) -- ... using a preventive medication, according to new research. That ... the late 1980s. Preventive asthma medications help control ... the U.S. National Asthma Education and Prevention Program recommend their ...
... available in German . , The extent ... depends on motivation and will power or the physical condition ... latter particularly leads to noticeable and measurable performance impairments. For ... confined to changes in the muscle itself. Now, a joint ...
... 4 (HealthDay News) -- Variations in genes involved in ... disorder (ADHD), according to a new study. The ... may offer a new treatment option for ADHD patients ... researchers said. In the study, researchers conducted whole-genome ...
Cached Medicine News:Health News:Risk for Dementia Rises When Diabetes, Depression Meet: Study 2Health News:Risk for Dementia Rises When Diabetes, Depression Meet: Study 3Health News:Preoperative aspirin therapy can benefit cardiac surgery patients 2Health News:Parents' views sought on childhood obesity risk 2Health News:More Children Using Preventive Asthma Drugs: Study 2Health News:More Children Using Preventive Asthma Drugs: Study 3Health News:How muscle fatigue originates in the head 2Health News:More Evidence Links Specific Genes to ADHD 2
... enhances productivity in the laboratory with its ... methods clotting, chromogenic and immunological ... test results every time. With user ... random access, the CA-1500 will provide you ...
... Premier is our top-of-the-line device. ... attributes of the Qwik-Let® Elite, ... Lan-X feature. The Lan-X technology ... protection in the removal and ...
... the pain and hassle of testing. Unlike ... device is the only one with a ... testing, with less hassle and improved safety. ... and no side-to-side motion for less skin ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
Medicine Products: